Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Clinical trial NCT03430518 · COMPLETED
Trial details
- NCT number
- NCT03430518
- Sponsor
- Amy Tiersten
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-17
- Primary completion
- 2020-02-10
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.